Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 | Experimental | Dose 1 |
|
| Cohort 2 | Experimental | Dose 2 |
|
| Cohort 3 | Experimental | Dose 3 |
|
| PDN cohort | Experimental | Dose based on safety in healthy Cohorts 1-3 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral dose CNTX-6016 or oral dose Placebo | Drug | CNTX-6016 or Placebo |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of treatment-emergent adverse events (TEAEs) (safety and tolerability) with CNTX-6016 | Number of participants with TEAEs, which includes laboratory test variables | Up to 45 days |
| CNTX-6016 Pharmacokinetics - Cmax | Systemic exposure to CNTX-6016 measured by Cmax | Up to Day 6 |
| CNTX-6016 Pharmacokinetics - AUC0-t | Systemic exposure to CNTX-6016 measured by AUC0-t | Up to Day 6 |
| CNTX-6016 Pharmacokinetics - t1/2 | Systemic exposure to CNTX-6016 measured by t1/2 | Up to Day 6 |
| CNTX-6016 Pharmacokinetics - tmax | Systemic exposure to CNTX-6016 measured by tmax | Up to Day 6 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| CNTX-6016 Effect of Age and Sex in all Cohorts | Systemic exposure to CNTX-6016 By Cmax pooled from all cohorts over full dose range. | Up to Day 14 |
| CNTX-6016 Effect of Age and Sex in all Cohorts | Systemic exposure to CNTX-6016 By AUC pooled from all cohorts over full dose range. |
Key Inclusion Criteria:
Key Exclusion Criteria:
Key Inclusion Criteria- PDN Cohort
Key Exclusion Criteria- PDN Cohort
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Randall Stevens, MD | Centrexion Therapeutics | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AltaSciences | Overland Park | Kansas | 66212 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003929 | Diabetic Neuropathies |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D048909 | Diabetes Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to Day 14 |
| CNTX-6016 Efficacy - PDN Cohort | Efficacy measured by Numeric Rating Scale. The Numeric Rating Scale is an 11-point pain scale with a range of 0 to 10 where 0 = "no pain" and 10 = "worst possible pain" | Up to Day 14 |
| CNTX-6016 Efficacy - PDN Cohort | Efficacy measured by PainDETECT Questionnaire | Up to Day 14 |
| CNTX-6016 Efficacy - PDN Cohort | Efficacy measured by Patient Global Impression of Change | Up to Day 14 |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |